NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AnaCardio

AnaCardio

Private
StockholmHealthcare & Life Scienceshttps://anacardio.com/

Last Round

Series A

Extension

Jan 9, 2025

Est. Valuation

$1.71M

Total Funding Raised

$34.24M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AnaCardio is a clinical-stage biopharmaceutical company that develops novel drugs to treat heart failure.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

heart failureHFrEFbiopharmaceuticalsmall molecule drugcardiac contractilityclinical trialsdrug developmentbiotech startupheart failure treatmentcardiovascular medicinedrug discoveryclinical researchpharma pipelinepreclinical pharmacology

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AnaCardio Comparables

Compare AnaCardio with similar companies based on industry and business-model similarity.

AnaCardio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Zensun (Shanghai) Sci & Tech Co., Ltd.
78%
Cardurion Pharmaceuticals
77%
Seismic Pharmaceutical Holdings
75%

AnaCardio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 9, 2025
Series ASep 8, 2022
VC RoundFeb 3, 2022
SeedJun 17, 2021

Key People

Founding team and executive leadership

Philipp Mathieu

Chief Financial Officer

Executive Team

Johan Sjödahl

Chief Operating Officer

Executive Team

AnaCardio Investors

Notable investors and investment history

AnaCardio investors
InvestorRounds
3B FUTURE Health FundSeries A
IndustrifondenSeries A Extension, VC Round, Series A
Novo HoldingsSeries A Extension
Karolinska Development ABSeries A, VC Round, Seed
Pureos BioventuresSeries A Extension
Flerie ABSeries A Extension, Series A
Sound BioventuresSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 15, 2026

    Monthly visitors increased 31% MoM.

  • Mar 26, 2026

    AC01 study selected for Late-Breaking Science at Heart Failure 2026 Congress.

AnaCardio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AnaCardio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AnaCardio's valuation, stock price, and market status.

Firmographic Details

HeadquartersStockholm
Employee Range26
Year Founded2017
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.